Company Profile

Stentys SA is a French-based company specialized in the development of a new generation of stents for the treatment of acute myocardial infarction or coronary artery disease. It's main product STENTYS Stent, self-expanding coronary bare-metal stent system, is indicated for the treatment of Acute Coronary Syndrome. The Company's institutional shareholders are Sofinnova Partners, Credit Agricole Private Equity and Scottish Equity Partners. In June 2014, it acquired Cappella Peel Away Inc.

Employees

Sector

Medical Equipment, Supplies & Distribution

More about the company

08/10/20	Stentys S.A. Reports Earnings Results for the Half Year Ended June 30, 2020	CI
16/05/20	STENTYS S.A. Announces Revenue Results for the First Quarter Of 2020	CI
15/10/19	Stentys Société Anonyme Reports Earnings Results for the Half Year Ended June 30, 2019	CI
12/04/19	Stentys S.A. Announces Revenue Results for the First Quarter 2019	CI
01/04/19	Stentys Société Anonyme Reports Earnings Results for the Full Year Ended December 31, 2018	CI
11/01/19	Stentys S.A. Announces Audited Revenue Results for the Fourth Quarter and Full Year Ended December 31, 2018	CI
12/10/18	STENTYS S.A. Announces Consolidated Revenue Results for the Third Quarter and Nine Months Ended September 30, 2018	CI
29/09/18	STENTYS Announces Earnings Results for the Six Months Ended June 30, 2018	CI
12/07/18	STENTYS S.A. Announces Unaudited Consolidated Revenue Results for the Second Quarter and First Half of 2018	CI
30/04/18	STENTYS S.A. completed the acquisition of Minvasys.	CI
13/04/18	STENTYS S.A. Reports Revenue Results for the First Quarter Ended March 31, 2018	CI
03/04/18	STENTYS S.A. Announces Audited Consolidated Earnings Results for the Year Ended December 31, 2017	CI
30/01/18	STENTYS S.A. entered into an exclusive negotiations agreement to acquire Minvasys for €7.4 million.	CI

16/05/20	STENTYS: Financial Information for the First Quarter Of 2020	BU
15/05/20	Stentys : Financial Information for the First Quarter of 2020	PU
07/05/20	Stentys : 2019 Annual Results	PU
23/10/19	Stentys : Convening of another Combined General Meeting on November 14, 2019	PU
15/10/19	Stentys : 2019 half-year results	PU

21/07/21	Plongée dans le business des OCABSA : Interview de Pierre Vannineuse
24/03/21	EN DIRECT DES MARCHES : Carrefour, EssilorLuxottica, Valneva, Tesla, Microsoft, Leonardo, Toyota, Intel, GameStop...
24/03/21	Stentys : L’Assemblée générale de STENTYS décide la dissolution anticipée de la Société
06/03/21	STENTYS : Convocation à une nouvelle Assemblée générale mixte le 23 mars 2021
03/03/21	EN DIRECT DES MARCHES : Danone, Schneider, Orange, CNP Assurances, Lumibird, Intel, Merck...

Manager	Title	Age	Since
Michel Darnaud CEO	Chief Executive Officer	76	10/05/2019
Tom Coles SAM	Sales & Marketing	-	01/03/2014
Alain Delabost SAM	Sales & Marketing	-	01/07/2018

Director	Title	Age	Since
Michel Darnaud CHM	Chairman	76	28/03/2018
Marie Meynadier BRD	Director/Board Member	64	03/02/2014
Christian M. Spaulding BRD	Director/Board Member	70	31/03/2017

Stentys Stock

Stocks

STNT

FR0010949404

Medical Equipment, Supplies & Distribution

Latest news: Stentys

Press Releases: Stentys

News in other languages: Stentys

Quotes and Performance

Managers and Directors: Stentys

Other Medical Equipment, Supplies & Distribution

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
STENTYS	-2.95%	-6.12%	-	-	16.76M
ABBOTT LABORATORIES	+1.12%	-4.84%	-22.91%	+0.43%	178B
MEDTRONIC PLC	+3.12%	-0.39%	-0.24%	+14.45%	120B
CENCORA, INC.	+1.45%	-1.43%	+7.84%	+84.32%	62.25B
HOYA CORPORATION	-0.45%	-4.27%	+3.07%	+33.55%	48.54B
BECTON, DICKINSON AND COMPANY	+2.85%	-0.99%	-2.10%	-30.88%	49.82B
DEXCOM, INC.	+1.99%	-3.66%	+11.10%	-16.61%	31.95B
MEDLINE INC.	+0.18%	-10.93%	-	-	28.59B
WEST PHARMACEUTICAL SERVICES, INC.	+2.59%	+4.48%	+40.12%	-10.73%	25B
TERUMO CORPORATION	-0.88%	-3.61%	-11.03%	+1.86%	21.59B
Average	+0.35%	-3.58%	+3.23%	+9.55%	62.9B
Weighted average by Cap.	+0.37%	-3.32%	-4.59%	+11.89%